The Pipeline of Therapeutics Testing During the Emergency Phase of the COVID-19 Outbreak

Frontiers in Medicine

article

Marco Canevelli¹  Nicola Vanacore¹  Valeria Raparelli³  Giulia Remoli²  Federica Trentin²  Gabriele Riccardi⁴  Leonardo Tariciotti⁵  Giovanni Risoleo⁶  Antonio Ancidoni¹  Giuseppe Bruno²  Matteo Cesari⁷ 

[1] National Center for Disease Prevention and Health Promotion, Italian National Institute of Health;Department of Human Neuroscience, Sapienza University of Rome;Department of Experimental Medicine, Sapienza University of Rome;Department of Sense Organ, Sapienza University of Rome;Unit of Neurosurgery, IRCSS Fondazione Cà Granda Ospedale Maggiore Policlinico, University of Milan;Department of Radiology, ASTT Grande Ospedale Metropolitano Niguarda, University of Milan;Department of Clinical Sciences and Community Health, University of Milan;Geriatric Unit, IRCCS Istituti Clinici Scientifici Maugeri

关键词: COVID-19;    SARS-CoV-2;    clinical trials;    antivirals;    immunomodulators;    research protocols;    drug development;   

DOI  :  10.3389/fmed.2020.552991

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

The coronavirus disease 19 (COVID-19) pandemic poses a serious threat to the sustainability of healthcare systems and is currently having a significant effect on living conditions worldwide. No therapeutic agent has yet proven to be effective for the treatment of COVID-19. The management of this disease currently relies on supportive care and the off-label and compassionate use of antivirals and immunomodulators. Nevertheless, there has been a great worldwide effort to progress research and test the efficacy and safety/tolerability profiles of numerous candidate agents that may positively affect the various clinical syndromes associated with COVID-19. In parallel, vaccination and chemoprophylaxis strategies are being investigated. This article provides a summary of interventional studies targeting COVID-19 during the emergency phase of the outbreak to broadly inform clinicians and researchers on what happened and what they can expect in upcoming months. The clinicaltrials.gov database and the European Union (EU) Clinical Trials Register were investigated on March 31, 2020, to identify all ongoing phase 1–4 research protocols testing pharmacological interventions targeting SARS-CoV-2 infection and/or clinical syndromes associated with COVID-19. Overall, six phase 1, four phase 1-2, 14 phase 2, ten phase 2-3, 19 phase 3, and nine phase 4 studies were identified, and the features of these studies are described in the present review. We also provide an updated overview of the change overtime in the pipeline following this emergency phase and based on the current epidemiology of the COVID-19 pandemic.

【 授权许可】

CC BY